Anti-CD19-CAR T cells will destroy not only all tumor cells but also healthy B cells resulting in a B cell aplasia which makes the host more prone to opportunistic infections that nonetheless can be managed with immunoglobulin treatment (10). This evidence concerns the gene CD19 and neoplasm.